Last update 21 Nov 2024

Lurbinectedin

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Lurbinectedin (USAN/INN), Lurbinectedina, Tryptamicidin
+ [8]
Target
Mechanism
DNA inhibitors(DNA inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (15 Jun 2020),
RegulationAccelerated Approval (US), Conditional marketing approval (IL), Emergency Use Authorization (CN), Orphan Drug (CH), Overseas New Drugs Urgently Needed in Clinical Settings (CN), Priority Review (US)
Login to view timeline

Structure

Molecular FormulaC41H44N4O10S
InChIKeyYDDMIZRDDREKEP-HWTBNCOESA-N
CAS Registry497871-47-3

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Small Cell Lung Cancer
SG
-
Small Cell Lung Cancer
CA
-
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Small cell lung cancer recurrentNDA/BLA
CN
07 Jun 2023
Small cell lung cancer recurrentNDA/BLA
CN
07 Jun 2023
Small cell lung cancer recurrentNDA/BLA
CN
07 Jun 2023
Small Cell Lung CancerNDA/BLA
HK
04 Mar 2022
Extensive stage Small Cell Lung CancerPhase 3
MX
18 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
PL
18 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
KR
18 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
TW
18 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
US
18 Nov 2021
Platinum-Resistant Ovarian CarcinomaDiscovery
US
01 May 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
-
(xqmcxpunww) = statistically significant improvement cnedbycvdk (kzrtdtsbvs )
Positive
16 Oct 2024
Phase 2
101
Lurbinectedin 2.0 mg/m^2 + Irinotecan 75 mg/m^2
(All pts with CTFI>30)
(wrcefbklhi) = lezkuhlspi udnalmlwum (thggzocmkd, 9.1 - 14.1)
Positive
14 Sep 2024
Lurbinectedin 2.0 mg/m^2 + Irinotecan 75 mg/m^2
(CTFI 30-90 d)
(wrcefbklhi) = lkftvqmnwy udnalmlwum (thggzocmkd, 3.7 - 13.6)
Phase 1/2
6
Lurbinectedin+ipilimumab+nivolumab
(totkaaqezj) = mmjqlifcqw dyibunxzuf (eujyfttyow )
Positive
14 Sep 2024
WCLC2024
ManualManual
Not Applicable
81
Platinum rechallenge
(qljxfzqngk) = gzpzbmacwg fcozzfxrmd (qsakawfgoc, 4.99 - 15.64)
Similar
08 Sep 2024
(qljxfzqngk) = qimgfqdyax fcozzfxrmd (qsakawfgoc, 2.62 - 7.40)
Not Applicable
92
Lurbinectedin monotherapy
(second-line)
(zcemrtpect) = tqtwnxesjm iuofoiuaus (bugzrdtpnf )
Positive
08 Sep 2024
Lurbinectedin monotherapy
(second-line + CTFI <90)
(zcemrtpect) = sybikhszsj iuofoiuaus (bugzrdtpnf )
Not Applicable
-
(ncclcwjbbx) = iieqwqgpno gjglvrguqa (nvopvjzapk )
-
08 Sep 2024
Not Applicable
-
(High SLFN11 expression)
duimmhwjke(nwqhfdjxrk) = vtyzvspogi dygyvunmhm (ruseveqben )
-
07 Sep 2024
(Low SLFN11 expression)
duimmhwjke(nwqhfdjxrk) = ryyzwmztdg dygyvunmhm (ruseveqben )
Phase 4
Small Cell Lung Cancer
Second line | Third line
105
Lurbinectedin
(2L)
(rphvmkmhhi) = rraemwvjpd fyticexzzb (fimhedonii )
Positive
24 May 2024
Lurbinectedin
(3L)
(rphvmkmhhi) = xlpgjaxadq fyticexzzb (fimhedonii )
Not Applicable
14
(ykqcfmxfcm) = rxerquauyf fqgypjkogq (zsqthwyymq, 2.17 - 13.63)
Positive
25 Jan 2024
Not Applicable
18
(lbxbgmyjgo) = There were no hospitalizations for L treatment related adverse events (tRAE). The most common tRAE were grade I and II fatigue and anemia; 9 pts (50%) experienced no tRAE. typnavknlc (vnfakarsmb )
Positive
25 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free